Early medical use of cannabis.[Nature. 1993]

Zias J, Stark H, Sellgman J, Levy R, Werker E, Breuer A, Mechoulam R

Nature. 1993 May 20; 363(6426):215.

Withdrawal symptoms in cannabis indica addicts.[Lancet. 1949]

FRASER JD

Lancet. 1949 Oct 22; 2(6582):747.
Review Treatment of cannabis use disorders: a review of the literature.[Am J Addict. 2007]

Nordstrom BR, Levin FR

Am J Addict. 2007 Sep-Oct; 16(5):331-42.
[Cannabis addiction and Telic Dominance Scale].[Encephale. 2003]

Bernoussi A, Brandibas G

Encephale. 2003 Nov-Dec; 29(6):519-26.
Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence.[J Consult Clin Psychol. 2006]

Budney AJ, Moore BA, Rocha HL, Higgins ST

J Consult Clin Psychol. 2006 Apr; 74(2):307-16.
Review Addictive potential of cannabinoids: the underlying neurobiology.[Chem Phys Lipids. 2002]

Gardner EL

Chem Phys Lipids. 2002 Dec 31; 121(1-2):267-90.
Review Cannabinoid addiction: behavioral models and neural correlates.[J Neurosci. 2002]

Maldonado R, Rodríguez de Fonseca F

J Neurosci. 2002 May 1; 22(9):3326-31.
Failure of Delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys.[Behav Pharmacol. 1994]

Mansbach RS, Nicholson KL, Martin BR, Balster RL

Behav Pharmacol. 1994 Apr; 5(2):219-225.

Review Endocannabinoid system and alcohol addiction: pharmacological studies.[Pharmacol Biochem Behav. 2005]

Colombo G, Serra S, Vacca G, Carai MA, Gessa GL

Pharmacol Biochem Behav. 2005 Jun; 81(2):369-80.
Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.[Proc Natl Acad Sci U S A. 2003]

Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G

Proc Natl Acad Sci U S A. 2003 Feb 4; 100(3):1393-8.
SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.[Behav Pharmacol. 2002]

Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P

Behav Pharmacol. 2002 Sep; 13(5-6):451-63.
The diagnosis of alcohol and cannabis dependence (addiction) in cocaine dependence (addiction).[Int J Addict. 1990]

Miller NS, Gold MS, Klahr AL

Int J Addict. 1990 Jul; 25(7):735-44.
Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans.[Drug Alcohol Depend. 1993]

Foltin RW, Fischman MW, Pippen PA, Kelly TH

Drug Alcohol Depend. 1993 Apr; 32(2):93-106.
Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers.[Pharmacol Biochem Behav. 1994]

Lukas SE, Sholar M, Kouri E, Fukuzako H, Mendelson JH

Pharmacol Biochem Behav. 1994 Jul; 48(3):715-21.
(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population.[Pharmacogenomics J. 2006]

Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO, Poirier MF

Pharmacogenomics J. 2006 Mar-Apr; 6(2):126-30.
Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.[Pharmacol Rep. 2006]

Filip M, Gołda A, Zaniewska M, McCreary AC, Nowak E, Kolasiewicz W, Przegaliński E

Pharmacol Rep. 2006 Nov-Dec; 58(6):806-19.
Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.[Neuroreport. 2004]

Le Foll B, Goldberg SR

Neuroreport. 2004 Sep 15; 15(13):2139-43.
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).[Neuropsychopharmacology. 2005]

Cohen C, Perrault G, Griebel G, Soubrié P

Neuropsychopharmacology. 2005 Jan; 30(1):145-55.
Review The role of the cannabinoid system in nicotine addiction.[Pharmacol Biochem Behav. 2005]

Castañé A, Berrendero F, Maldonado R

Pharmacol Biochem Behav. 2005 Jun; 81(2):381-6.
[A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes].[MMW Fortschr Med. 2004]

Einecke D

MMW Fortschr Med. 2004 Mar 25; 146(13):10-1.
Review Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.[Expert Opin Investig Drugs. 2006]

Gelfand EV, Cannon CP

Expert Opin Investig Drugs. 2006 Mar; 15(3):307-15.
Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats.[Proc Natl Acad Sci U S A. 2006]

Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I

Proc Natl Acad Sci U S A. 2006 May 16; 103(20):7877-82.
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.[Science. 1999]

Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M

Science. 1999 Jan 15; 283(5400):401-4.
Review The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction.[Cell Mol Life Sci. 2006]

Laviolette SR, Grace AA

Cell Mol Life Sci. 2006 Jul; 63(14):1597-613.
Review Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.[J Pharmacol Exp Ther. 2005]

Le Foll B, Goldberg SR

J Pharmacol Exp Ther. 2005 Mar; 312(3):875-83.

Cognitive functioning of long-term heavy cannabis users seeking treatment.[JAMA. 2002]

Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J, Marijuana Treatment Project Research Group.

JAMA. 2002 Mar 6; 287(9):1123-31.
Chronic cognitive impairment in users of 'ecstasy' and cannabis.[World Psychiatry. 2003]

Klugman A, Gruzelier J

World Psychiatry. 2003 Oct; 2(3):184-90.
Cannabis use, cognitive performance and mood in a sample of workers.[J Psychopharmacol. 2006]

Wadsworth EJ, Moss SC, Simpson SA, Smith AP

J Psychopharmacol. 2006 Jan; 20(1):14-23.
Long-term effects of frequent cannabis use on working memory and attention: an fMRI study.[Psychopharmacology (Berl). 2006]

Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF

Psychopharmacology (Berl). 2006 Apr; 185(3):358-68.
Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1- naphthalenylmethanone.[Eur J Neurosci. 2007]

Maj PF, Collu M, Fadda P, Cattaneo A, Racagni G, Riva MA

Eur J Neurosci. 2007 Jun; 25(11):3305-11.
Review A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function.[Neurotoxicol Teratol. 2001]

Fried PA, Smith AM

Neurotoxicol Teratol. 2001 Jan-Feb; 23(1):1-11.
Review Cannabis, the mind and society: the hash realities.[Nat Rev Neurosci. 2007]

Murray RM, Morrison PD, Henquet C, Di Forti M

Nat Rev Neurosci. 2007 Nov; 8(11):885-95.
Review Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?[J Psychiatry Neurosci. 2007]

Solowij N, Michie PT

J Psychiatry Neurosci. 2007 Jan; 32(1):30-52.
Two cases of "cannabis acute psychosis" following the administration of oral cannabis.[BMC Psychiatry. 2005]

Favrat B, Ménétrey A, Augsburger M, Rothuizen LE, Appenzeller M, Buclin T, Pin M, Mangin P, Giroud C

BMC Psychiatry. 2005 Apr 1; 5():17.
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.[Neuropsychopharmacology. 2004]

D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH

Neuropsychopharmacology. 2004 Aug; 29(8):1558-72.
Review [Amotivational syndrome in organic solvent abusers].[Nihon Yakurigaku Zasshi. 2001]

Ozaki S, Wada K

Nihon Yakurigaku Zasshi. 2001 Jan; 117(1):42-8.
Review [Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats].[Nihon Yakurigaku Zasshi. 2001]

Fujiwara M

Nihon Yakurigaku Zasshi. 2001 Jan; 117(1):35-41.
Psychiatric aspects of cannabis use in adolescents and young adults.[Pediatrician. 1987]

Tunving K

Pediatrician. 1987; 14(1-2):83-91.
Review Treatment of cannabis use disorders: a review of the literature.[Am J Addict. 2007]

Nordstrom BR, Levin FR

Am J Addict. 2007 Sep-Oct; 16(5):331-42.
[Related, induced and associated psychiatric disorders to cannabis].[Rev Prat. 2005]

Laqueille X

Rev Prat. 2005 Jan 15; 55(1):30-4.
Operant acquisition of marihuana in man.[J Pharmacol Exp Ther. 1976]

Mendelson JH, Kuehnle JC, Greenberg I, Mello NK

J Pharmacol Exp Ther. 1976 Jul; 198(1):42-53.
Cannabis, motivation, and life satisfaction in an internet sample.[Subst Abuse Treat Prev Policy. 2006]

Barnwell SS, Earleywine M, Wilcox R

Subst Abuse Treat Prev Policy. 2006 Jan 12; 1():2.
Cannabinoid-induced pancreatitis: a case series.[JOP. 2007]

Wargo KA, Geveden BN, McConnell VJ

JOP. 2007 Sep 7; 8(5):579-83.

Review Endocannabinoids in the regulation of appetite and body weight.[Behav Pharmacol. 2005]

Kirkham TC

Behav Pharmacol. 2005 Sep; 16(5-6):297-313.
Review Endocannabinoids in appetite control and the treatment of obesity.[CNS Neurol Disord Drug Targets. 2006]

Kirkham TC, Tucci SA

CNS Neurol Disord Drug Targets. 2006 Jun; 5(3):272-92.
Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men.[J Clin Endocrinol Metab. 2007]

Russo P, Strazzullo P, Cappuccio FP, Tregouet DA, Lauria F, Loguercio M, Barba G, Versiero M, Siani A

J Clin Endocrinol Metab. 2007 Jun; 92(6):2382-6.
Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats.[Psychopharmacology (Berl). 2006]

Gessa GL, Orrù A, Lai P, Maccioni P, Lecca R, Lobina C, Carai MA, Colombo G

Psychopharmacology (Berl). 2006 Apr; 185(2):248-54.
The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940).[Behav Pharmacol. 2005]

Ward SJ, Dykstra LA

Behav Pharmacol. 2005 Sep; 16(5-6):381-8.
SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.[Behav Pharmacol. 1998]

Simiand J, Keane M, Keane PE, Soubrié P

Behav Pharmacol. 1998 Mar; 9(2):179-81.

Review Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.[CNS Drug Rev. 2006]

Carai MA, Colombo G, Maccioni P, Gessa GL

CNS Drug Rev. 2006 Summer; 12(2):91-9.
Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.[Lancet. 2005]

Pagotto U, Pasquali R

Lancet. 2005 Apr 16-22; 365(9468):1363-4.
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.[N Engl J Med. 2005]

Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group.

N Engl J Med. 2005 Nov 17; 353(20):2121-34.
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.[JAMA. 2006]

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group.

JAMA. 2006 Feb 15; 295(7):761-75.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.[Lancet. 2005]

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, RIO-Europe Study Group.

Lancet. 2005 Apr 16-22; 365(9468):1389-97.
Review Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.[Eur J Heart Fail. 2004]

Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP

Eur J Heart Fail. 2004 Jun; 6(4):501-8.
Review [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].[Rev Med Suisse. 2006]

Scheen AJ, Van Gaal LG, Després JP, Pi-Sunyer X, Golay A, Hanotin C

Rev Med Suisse. 2006 Aug 23; 2(76):1916-23.
Rimonabant in obese patients with type 2 diabetes.[Lancet. 2007]

Shapiro H, Singer P

Lancet. 2007 Feb 17; 369(9561):553-4; author reply 554-5.
Review Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.[Expert Opin Investig Drugs. 2006]

Gelfand EV, Cannon CP

Expert Opin Investig Drugs. 2006 Mar; 15(3):307-15.
Review Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.[Am J Health Syst Pharm. 2007]

Patel PN, Pathak R

Am J Health Syst Pharm. 2007 Mar 1; 64(5):481-9.

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.[J Pain Symptom Manage. 1997]

Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV

J Pain Symptom Manage. 1997 Jul; 14(1):7-14.
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.[J Pain Symptom Manage. 1995]

Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV

J Pain Symptom Manage. 1995 Feb; 10(2):89-97.
Dronabinol effects on weight in patients with HIV infection.[AIDS. 1992]

Gorter R, Seefried M, Volberding P

AIDS. 1992 Jan; 6(1):127.
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative.[AIDS Res Hum Retroviruses. 1997]

Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G

AIDS Res Hum Retroviruses. 1997 Mar 1; 13(4):305-15.
Review [Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients].[Schmerz. 2004]

Nauck F, Klaschik E

Schmerz. 2004 Jun; 18(3):197-202.
Review A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia.[J Palliat Care. 1994]

Nelson K, Walsh D, Deeter P, Sheehan F

J Palliat Care. 1994 Spring; 10(1):14-8.
Review Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain.[J Support Oncol. 2004]

Martin BR, Wiley JL

J Support Oncol. 2004 Jul-Aug; 2(4):305-14; discussion 314-6.
An efficient new cannabinoid antiemetic in pediatric oncology.[Life Sci. 1995]

Abrahamov A, Abrahamov A, Mechoulam R

Life Sci. 1995; 56(23-24):2097-102.
Review Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.[BMJ. 2001]

Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ

BMJ. 2001 Jul 7; 323(7303):16-21.

Review Therapeutic potential of cannabinoids in trigeminal neuralgia.[Curr Drug Targets CNS Neurol Disord. 2004]

Liang YC, Huang CC, Hsu KS

Curr Drug Targets CNS Neurol Disord. 2004 Dec; 3(6):507-14.
Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients.[Int J Clin Pharmacol Res. 1985]

Volfe Z, Dvilansky A, Nathan I

Int J Clin Pharmacol Res. 1985; 5(4):243-6.
Are oral cannabinoids safe and effective in refractory neuropathic pain?[Eur J Pain. 2004]

Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D

Eur J Pain. 2004 Apr; 8(2):173-7.
Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain.[Pain. 2003]

Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ

Pain. 2003 Nov; 106(1-2):169-72.
Pain relief with oral cannabinoids in familial Mediterranean fever.[Anaesthesia. 1997]

Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F

Anaesthesia. 1997 May; 52(5):483-6.
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.[Pain. 2004]

Berman JS, Symonds C, Birch R

Pain. 2004 Dec; 112(3):299-306.
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.[BMJ. 2004]

Svendsen KB, Jensen TS, Bach FW

BMJ. 2004 Jul 31; 329(7460):253.
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication].[Ugeskr Laeger. 2005]

Svendsen KB, Jensen TS, Bach FW

Ugeskr Laeger. 2005 Jun 20; 167(25-31):2772-4.
The analgesic properties of delta-9-tetrahydrocannabinol and codeine.[Clin Pharmacol Ther. 1975]

Noyes R Jr, Brunk SF, Avery DA, Canter AC

Clin Pharmacol Ther. 1975 Jul; 18(1):84-9.
Analgesic effect of delta-9-tetrahydrocannabinol.[J Clin Pharmacol. 1975]

Noyes R Jr, Brunk SF, Baram DA, Canter A

J Clin Pharmacol. 1975 Feb-Mar; 15(2-3):139-43.
Cannabis use for chronic non-cancer pain: results of a prospective survey.[Pain. 2003]

Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ

Pain. 2003 Mar; 102(1-2):211-6.
Cannabis use in HIV for pain and other medical symptoms.[J Pain Symptom Manage. 2005]

Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A

J Pain Symptom Manage. 2005 Apr; 29(4):358-67.
Experience with the synthetic cannabinoid nabilone in chronic noncancer pain.[Pain Med. 2006]

Berlach DM, Shir Y, Ware MA

Pain Med. 2006 Jan-Feb; 7(1):25-9.
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.[J Neurol. 2006]

Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD

J Neurol. 2006 Oct; 253(10):1337-41.
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.[JAMA. 2003]

Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U

JAMA. 2003 Oct 1; 290(13):1757-62.
Cannabimimetic properties of ajulemic acid.[J Pharmacol Exp Ther. 2007]

Vann RE, Cook CD, Martin BR, Wiley JL

J Pharmacol Exp Ther. 2007 Feb; 320(2):678-86.

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.[Med Hypotheses. 2006]

Russo E, Guy GW

Med Hypotheses. 2006; 66(2):234-46.
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.[Curr Med Res Opin. 2007]

Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR

Curr Med Res Opin. 2007 Jan; 23(1):17-24.
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.[Anaesthesia. 2004]

Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C

Anaesthesia. 2004 May; 59(5):440-52.
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.[Neurology. 2005]

Rog DJ, Nurmikko TJ, Friede T, Young CA

Neurology. 2005 Sep 27; 65(6):812-9.
Review Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.[Expert Opin Pharmacother. 2006]

Barnes MP

Expert Opin Pharmacother. 2006 Apr; 7(5):607-15.

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.[BMJ. 2004]

Svendsen KB, Jensen TS, Bach FW

BMJ. 2004 Jul 31; 329(7460):253.
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication].[Ugeskr Laeger. 2005]

Svendsen KB, Jensen TS, Bach FW

Ugeskr Laeger. 2005 Jun 20; 167(25-31):2772-4.
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.[Curr Med Res Opin. 2007]

Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR

Curr Med Res Opin. 2007 Jan; 23(1):17-24.
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.[Neurology. 2005]

Rog DJ, Nurmikko TJ, Friede T, Young CA

Neurology. 2005 Sep 27; 65(6):812-9.
Review Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.[Expert Opin Pharmacother. 2006]

Barnes MP

Expert Opin Pharmacother. 2006 Apr; 7(5):607-15.
Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.[J Neuroimmunol. 2000]

Achiron A, Miron S, Lavie V, Margalit R, Biegon A

J Neuroimmunol. 2000 Jan 3; 102(1):26-31.
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.[J Neuroimmunol. 1989]

Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB

J Neuroimmunol. 1989 Jun; 23(1):73-81.
R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.[Biochem Pharmacol. 2006]

Sánchez AJ, González-Pérez P, Galve-Roperh I, García-Merino A

Biochem Pharmacol. 2006 Dec 15; 72(12):1697-706.
Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.[Mol Cell Neurosci. 2007]

Docagne F, Muñetón V, Clemente D, Ali C, Loría F, Correa F, Hernangómez M, Mestre L, Vivien D, Guaza C

Mol Cell Neurosci. 2007 Apr; 34(4):551-61.
Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.[J Neurosci. 2007]

Benito C, Romero JP, Tolón RM, Clemente D, Docagne F, Hillard CJ, Guaza C, Romero J

J Neurosci. 2007 Feb 28; 27(9):2396-402.
Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice.[Brain Res. 2006]

Cabranes A, Pryce G, Baker D, Fernández-Ruiz J

Brain Res. 2006 Aug 30; 1107(1):199-205.
Marihuana as a therapeutic agent for muscle spasm or spasticity.[Psychosomatics. 1980]

Petro DJ

Psychosomatics. 1980 Jan; 21(1):81, 85.
Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.[Br J Pharmacol. 2007]

Pryce G, Baker D

Br J Pharmacol. 2007 Feb; 150(4):519-25.
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.[Adv Alcohol Subst Abuse. 1987]

Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW

Adv Alcohol Subst Abuse. 1987; 7(1):39-50.
Nabilone in the treatment of multiple sclerosis.[Lancet. 1995]

Martyn CN, Illis LS, Thom J

Lancet. 1995 Mar 4; 345(8949):579.
Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.[J Neurol. 1989]

Meinck HM, Schönle PW, Conrad B

J Neurol. 1989 Feb; 236(2):120-2.
Treatment of human spasticity with delta 9-tetrahydrocannabinol.[J Clin Pharmacol. 1981]

Petro DJ, Ellenberger C Jr

J Clin Pharmacol. 1981 Aug-Sep; 21(S1):413S-416S.
The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.[Int J Clin Pharmacol Ther. 1996]

Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y

Int J Clin Pharmacol Ther. 1996 Oct; 34(10):446-52.
Review Tremor in multiple sclerosis.[J Neurol. 2007]

Koch M, Mostert J, Heersema D, De Keyser J

J Neurol. 2007 Feb; 254(2):133-45.
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.[Neurology. 2002]

Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH

Neurology. 2002 May 14; 58(9):1404-7.
Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers.[Clin Pharmacol Ther. 1994]

Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF

Clin Pharmacol Ther. 1994 Mar; 55(3):324-8.
Tetrahydrocannabinol for tremor in multiple sclerosis.[Ann Neurol. 1983]

Clifford DB

Ann Neurol. 1983 Jun; 13(6):669-71.
The effect of cannabis on tremor in patients with multiple sclerosis.[Neurology. 2004]

Fox P, Bain PG, Glickman S, Carroll C, Zajicek J

Neurology. 2004 Apr 13; 62(7):1105-9.
Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis.[Neurology. 1999]

Schon F, Hart PE, Hodgson TL, Pambakian AL, Ruprah M, Williamson EM, Kennard C

Neurology. 1999 Dec 10; 53(9):2209-10.
The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).[Int Urogynecol J Pelvic Floor Dysfunct. 2006]

Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J

Int Urogynecol J Pelvic Floor Dysfunct. 2006 Nov; 17(6):636-41.
GW-1000. GW Pharmaceuticals.[Curr Opin Investig Drugs. 2004]

Smith PF

Curr Opin Investig Drugs. 2004 Jul; 5(7):748-54.
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.[Mult Scler. 2004]

Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M

Mult Scler. 2004 Aug; 10(4):417-24.
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.[Mult Scler. 2004]

Wade DT, Makela P, Robson P, House H, Bateman C

Mult Scler. 2004 Aug; 10(4):434-41.
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.[Mult Scler. 2006]

Wade DT, Makela PM, House H, Bateman C, Robson P

Mult Scler. 2006 Oct; 12(5):639-45.
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.[Lancet. 2003]

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, UK MS Research Group.

Lancet. 2003 Nov 8; 362(9395):1517-26.
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.[J Neurol Neurosurg Psychiatry. 2005]

Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ

J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1664-9.
Review Combined cannabinoid therapy via an oromucosal spray.[Drugs Today (Barc). 2006]

Perez J

Drugs Today (Barc). 2006 Aug; 42(8):495-503.
From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches.[Mult Scler. 2007]

Bifulco M, Laezza C, Malfitano AM

Mult Scler. 2007 Jan; 13(1):133-4.
Review [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis].[Rev Neurol. 2006]

Mestre L, Correa F, Docagne F, Clemente D, Ortega-Gutiérrez S, Arévalo-Martín A, Molina-Holgado E, Borrell J, Guaza C

Rev Neurol. 2006 Nov 1-15; 43(9):541-8.

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.[Neurobiol Dis. 2005]

Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J

Neurobiol Dis. 2005 Jun-Jul; 19(1-2):96-107.
Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.[Acta Neuropathol. 2006]

Sommer C, Schomacher M, Berger C, Kuhnert K, Müller HD, Schwab S, Schäbitz WR

Acta Neuropathol. 2006 Sep; 112(3):277-86.
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.[Crit Care Med. 2002]

Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A

Crit Care Med. 2002 Mar; 30(3):548-54.
Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.[Lancet Neurol. 2006]

Maas AI, Murray G, Henney H 3rd, Kassem N, Legrand V, Mangelus M, Muizelaar JP, Stocchetti N, Knoller N, Pharmos TBI investigators.

Lancet Neurol. 2006 Jan; 5(1):38-45.
Review [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis].[Rev Neurol. 2006]

Mestre L, Correa F, Docagne F, Clemente D, Ortega-Gutiérrez S, Arévalo-Martín A, Molina-Holgado E, Borrell J, Guaza C

Rev Neurol. 2006 Nov 1-15; 43(9):541-8.
Review Cannabinoid-based drugs as anti-inflammatory therapeutics.[Nat Rev Immunol. 2005]

Klein TW

Nat Rev Immunol. 2005 May; 5(5):400-11.
Review Cannabinoids and neuroinflammation.[Br J Pharmacol. 2004]

Walter L, Stella N

Br J Pharmacol. 2004 Mar; 141(5):775-85.
Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation.[Neuroscience. 2007]

Marchalant Y, Rosi S, Wenk GL

Neuroscience. 2007 Feb 23; 144(4):1516-22.
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.[Nat Med. 2007]

Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN

Nat Med. 2007 Apr; 13(4):492-7.

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.[Nature. 2005]

Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F

Nature. 2005 Apr 7; 434(7034):782-6.
Review Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies.[Neuropharmacology. 2005]

Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, Sorrentini I, Di Marzo V

Neuropharmacology. 2005 Jun; 48(8):1154-63.
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.[Am J Physiol Heart Circ Physiol. 2007]

Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Drel VR, Obrosova IG, Pacher P

Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H610-9.

Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.[Br J Pharmacol. 2007]

Croci T, Zarini E

Br J Pharmacol. 2007 Mar; 150(5):559-66.

Review The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.[Prog Neurobiol. 2007]

Maccarrone M, Battista N, Centonze D

Prog Neurobiol. 2007 Apr; 81(5-6):349-79.
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.[Neurobiol Dis. 2005]

Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J

Neurobiol Dis. 2005 Jun-Jul; 19(1-2):96-107.

Review CB1 cannabinoid receptor signalling in Parkinson's disease.[Curr Opin Pharmacol. 2003]

Brotchie JM

Curr Opin Pharmacol. 2003 Feb; 3(1):54-61.
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.[Exp Neurol. 1997]

Maneuf YP, Crossman AR, Brotchie JM

Exp Neurol. 1997 Nov; 148(1):265-70.
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.[Eur J Neurosci. 2003]

Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A

Eur J Neurosci. 2003 Sep; 18(6):1607-14.
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.[Brain Res. 2006]

González S, Scorticati C, García-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J

Brain Res. 2006 Feb 16; 1073-1074():209-19.
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.[Eur J Neurosci. 2001]

Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ

Eur J Neurosci. 2001 Dec; 14(11):1827-32.
High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.[Ann Neurol. 2005]

Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agrò A, Bernardi G, Brusa L, Pierantozzi M, Stanzione P, Maccarrone M

Ann Neurol. 2005 May; 57(5):777-9.
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.[Nature. 2007]

Kreitzer AC, Malenka RC

Nature. 2007 Feb 8; 445(7128):643-7.
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.[Neurology. 2001]

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM

Neurology. 2001 Dec 11; 57(11):2108-11.
Delta9-tetrahydrocannabinol improves motor control in a patient with musician's dystonia.[Mov Disord. 2004]

Jabusch HC, Schneider U, Altenmüller E

Mov Disord. 2004 Aug; 19(8):990-1.
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.[Neurology. 2004]

Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP

Neurology. 2004 Oct 12; 63(7):1245-50.
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.[Mov Disord. 2002]

Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM

Mov Disord. 2002 Jan; 17(1):145-9.
Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.[Clin Neuropharmacol. 2004]

Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, Le Fur G, Damier P, Welter ML, Agid Y

Clin Neuropharmacol. 2004 May-Jun; 27(3):108-10.
Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms.[Mov Disord. 2004]

Venderová K, Růzicka E, Vorísek V, Visnovský P

Mov Disord. 2004 Sep; 19(9):1102-6.
Review Implication of cannabinoids in neurological diseases.[Cell Mol Neurobiol. 2006]

Alsasua del Valle A

Cell Mol Neurobiol. 2006 Jul-Aug; 26(4-6):579-91.
Review Potential role of cannabinoids in Parkinson's disease.[Drugs Aging. 2000]

Sevcík J, Masek K

Drugs Aging. 2000 Jun; 16(6):391-5.

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.[Neuroscience. 2000]

Glass M, Dragunow M, Faull RL

Neuroscience. 2000; 97(3):505-19.
Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus.[Ann Neurol. 1994]

Richfield EK, Herkenham M

Ann Neurol. 1994 Oct; 36(4):577-84.
Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.[Neuroscience. 1993]

Glass M, Faull RL, Dragunow M

Neuroscience. 1993 Oct; 56(3):523-7.
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.[Brain Res. 2005]

de Lago E, Urbani P, Ramos JA, Di Marzo V, Fernández-Ruiz J

Brain Res. 2005 Jul 19; 1050(1-2):210-6.
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.[J Neurochem. 2003]

Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J

J Neurochem. 2003 Mar; 84(5):1097-109.
The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.[Neuropharmacology. 2006]

Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML, Pèzzola A, Coccurello R, Felici F, Cuomo V, Piomelli D, Calamandrei G, Popoli P

Neuropharmacology. 2006 Oct; 51(5):1004-12.
Controlled clinical trial of cannabidiol in Huntington's disease.[Pharmacol Biochem Behav. 1991]

Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K

Pharmacol Biochem Behav. 1991 Nov; 40(3):701-8.

Review Cannabinoids reduce symptoms of Tourette's syndrome.[Expert Opin Pharmacother. 2003]

Müller-Vahl KR

Expert Opin Pharmacother. 2003 Oct; 4(10):1717-25.
Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.[Neuropsychopharmacology. 2003]

Müller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U

Neuropsychopharmacology. 2003 Feb; 28(2):384-8.
Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.[Pharmacopsychiatry. 2002]

Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, Emrich HM

Pharmacopsychiatry. 2002 Mar; 35(2):57-61.
Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.[J Clin Psychiatry. 2003]

Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM

J Clin Psychiatry. 2003 Apr; 64(4):459-65.
Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene.[Am J Med Genet B Neuropsychiatr Genet. 2004]

Gadzicki D, Müller-Vahl KR, Heller D, Ossege S, Nöthen MM, Hebebrand J, Stuhrmann M

Am J Med Genet B Neuropsychiatr Genet. 2004 May 15; 127B(1):97-103.

Review Marijuana in the management of amyotrophic lateral sclerosis.[Am J Hosp Palliat Care. 2001]

Carter GT, Rosen BS

Am J Hosp Palliat Care. 2001 Jul-Aug; 18(4):264-70.
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.[FASEB J. 2006]

Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L

FASEB J. 2006 May; 20(7):1003-5.
Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.[Amyotroph Lateral Scler Other Motor Neuron Disord. 2004]

Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Mar; 5(1):33-9.
Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival.[Amyotroph Lateral Scler Other Motor Neuron Disord. 2005]

Weydt P, Hong S, Witting A, Möller T, Stella N, Kliot M

Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Sep; 6(3):182-4.
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.[Eur J Pharmacol. 2006]

Kim K, Moore DH, Makriyannis A, Abood ME

Eur J Pharmacol. 2006 Aug 7; 542(1-3):100-5.
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.[J Neurochem. 2007]

Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL

J Neurochem. 2007 Apr; 101(1):87-98.
Survey of cannabis use in patients with amyotrophic lateral sclerosis.[Am J Hosp Palliat Care. 2004]

Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT

Am J Hosp Palliat Care. 2004 Mar-Apr; 21(2):95-104.
A molecular link between the active component of marijuana and Alzheimer's disease pathology.[Mol Pharm. 2006]

Eubanks LM, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ, Dickerson TJ, Janda KD

Mol Pharm. 2006 Nov-Dec; 3(6):773-7.
Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease.[Int J Geriatr Psychiatry. 1997]

Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ

Int J Geriatr Psychiatry. 1997 Sep; 12(9):913-9.
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.[Psychopharmacology (Berl). 2006]

Walther S, Mahlberg R, Eichmann U, Kunz D

Psychopharmacology (Berl). 2006 May; 185(4):524-8.

Anticonvulsant activity of four oxygenated cannabidiol derivatives.[Res Commun Chem Pathol Pharmacol. 1975]

Carlini EA, Mechoulam R, Lander N

Res Commun Chem Pathol Pharmacol. 1975 Sep; 12(1):1-15.
Antiepileptic potential of cannabidiol analogs.[J Clin Pharmacol. 1981]

Consroe P, Martin A, Singh V

J Clin Pharmacol. 1981 Aug-Sep; 21(S1):428S-436S.
Anticonvulsant effect of cannabidiol.[S Afr Med J. 1986]

Ames FR, Cridland S

S Afr Med J. 1986 Jan 4; 69(1):14.
Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.[J Pharmacol Exp Ther. 1977]

Consroe P, Wolkin A

J Pharmacol Exp Ther. 1977 Apr; 201(1):26-32.
Anticonvulsant interaction of cannabidiol and ethosuximide in rats.[J Pharm Pharmacol. 1977]

Consroe PF, Wolkin AL

J Pharm Pharmacol. 1977 Aug; 29(8):500-1.
Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy.[Med Hypotheses. 2007]

Cortesi M, Fusar-Poli P

Med Hypotheses. 2007; 68(4):920-1.
Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy.[Neurosci Lett. 2007]

Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ

Neurosci Lett. 2007 Jan 3; 411(1):11-6.
Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.[Eur J Pharmacol. 2006]

Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ

Eur J Pharmacol. 2006 Oct 10; 547(1-3):65-74.
Review Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy.[Epilepsia. 2001]

Gordon E, Devinsky O

Epilepsia. 2001 Oct; 42(10):1266-72.
Grand mal convulsions subsequent to marijuana use. Case report.[Dis Nerv Syst. 1967]

Keeler MH, Reifler CB

Dis Nerv Syst. 1967 Jul; 28(7 Pt 1):474-5.
Chronic administration of cannabidiol to healthy volunteers and epileptic patients.[Pharmacology. 1980]

Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R

Pharmacology. 1980; 21(3):175-85.

Review Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.[J Psychopharmacol. 2005]

Ashton CH, Moore PB, Gallagher P, Young AH

J Psychopharmacol. 2005 May; 19(3):293-300.
The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research.[J Psychoactive Drugs. 1998]

Grinspoon L, Bakalar JB

J Psychoactive Drugs. 1998 Apr-Jun; 30(2):171-7.

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.[Pharmacol Biochem Behav. 1997]

Emrich HM, Leweke FM, Schneider U

Pharmacol Biochem Behav. 1997 Apr; 56(4):803-7.
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.[Schizophr Res. 2007]

Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D

Schizophr Res. 2007 Aug; 94(1-3):29-36.
[Clinical features of cannabis psychosis in schizophrenia patients].[Georgian Med News. 2006]

Kenchadze VG, Chkoniia ED

Georgian Med News. 2006 Aug; (137):55-8.
Cannabis and acute psychosis.[Schizophr Res. 1994]

McGuire PK, Jones P, Harvey I, Bebbington P, Toone B, Lewis S, Murray RM

Schizophr Res. 1994 Sep; 13(2):161-7.
[Schizophrenia and cannabis consumption: epidemiology and clinical symptoms].[Prax Kinderpsychol Kinderpsychiatr. 2006]

Jockers-Scherübl MC

Prax Kinderpsychol Kinderpsychiatr. 2006; 55(7):533-43.
A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis.[Schizophr Res. 2007]

Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R

Schizophr Res. 2007 Jul; 93(1-3):203-10.
Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction.[Schizophr Res. 2006]

Dubertret C, Bidard I, Adès J, Gorwood P

Schizophr Res. 2006 Sep; 86(1-3):284-90.
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.[Am J Psychiatry. 2004]

Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group.

Am J Psychiatry. 2004 Jun; 161(6):975-84.

Antipsychotic effect of cannabidiol.[J Clin Psychiatry. 1995]

Zuardi AW, Morais SL, Guimarães FS, Mechoulam R

J Clin Psychiatry. 1995 Oct; 56(10):485-6.
Review Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.[Braz J Med Biol Res. 2006]

Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS

Braz J Med Biol Res. 2006 Apr; 39(4):421-9.

Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear.[Neuropsychopharmacology. 2005]

Chhatwal JP, Davis M, Maguschak KA, Ressler KJ

Neuropsychopharmacology. 2005 Mar; 30(3):516-24.
Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.[Neuropsychopharmacology. 2007]

Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH

Neuropsychopharmacology. 2007 May; 32(5):1032-41.
Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice.[Behav Pharmacol. 2005]

Fride E, Suris R, Weidenfeld J, Mechoulam R

Behav Pharmacol. 2005 Sep; 16(5-6):431-40.
Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder.[J Consult Clin Psychol. 2000]

Calhoun PS, Sampson WS, Bosworth HB, Feldman ME, Kirby AC, Hertzberg MA, Wampler TP, Tate-Williams F, Moore SD, Beckham JC

J Consult Clin Psychol. 2000 Oct; 68(5):923-7.
Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).[Pharmacogenomics J. 2005]

Barrero FJ, Ampuero I, Morales B, Vives F, de Dios Luna Del Castillo J, Hoenicka J, García Yébenes J

Pharmacogenomics J. 2005; 5(2):135-41.

Antianxiety effect of cannabidiol in the elevated plus-maze.[Psychopharmacology (Berl). 1990]

Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW

Psychopharmacology (Berl). 1990; 100(4):558-9.
Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.[Gen Pharmacol. 1994]

Guimarães FS, de Aguiar JC, Mechoulam R, Breuer A

Gen Pharmacol. 1994 Jan; 25(1):161-4.
A single dose study of nabilone, a synthetic cannabinoid.[Psychopharmacology (Berl). 1980]

Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW

Psychopharmacology (Berl). 1980; 71(2):137-42.
The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety.[J Clin Pharmacol. 1981]

Fabre LF, McLendon D

J Clin Pharmacol. 1981 Aug-Sep; 21(S1):377S-382S.

The effects of marijuana on human sleep patterns.[Biol Psychiatry. 1974]

Barratt ES, Beaver W, White R

Biol Psychiatry. 1974 Feb; 8(1):47-54.
Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns.[Clin Pharmacol Ther. 1972]

Pivik RT, Zarcone V, Dement WC, Hollister LE

Clin Pharmacol Ther. 1972 May-Jun; 13(3):426-35.
Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns.[Clin Pharmacol Ther. 1976]

Feinberg I, Jones R, Walker J, Cavness C, Floyd T

Clin Pharmacol Ther. 1976 Jun; 19(6):782-94.
Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man.[Clin Pharmacol Ther. 1975]

Feinberg I, Jones R, Walker JM, Cavness C, March J

Clin Pharmacol Ther. 1975 Apr; 17(4):458-66.
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.[J Clin Psychopharmacol. 2004]

Nicholson AN, Turner C, Stone BM, Robson PJ

J Clin Psychopharmacol. 2004 Jun; 24(3):305-13.

Effects of smoked marijuana in experimentally induced asthma.[Am Rev Respir Dis. 1975]

Tashkin DP, Shapiro BJ, Lee YE, Harper CE

Am Rev Respir Dis. 1975 Sep; 112(3):377-86.
Respiratory status of seventy-four habitual marijuana smokers.[Chest. 1980]

Tashkin DP, Calvarese BM, Simmons MS, Shapiro BJ

Chest. 1980 Nov; 78(5):699-706.
Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects.[Chest. 1976]

Abboud RT, Sanders HD

Chest. 1976 Oct; 70(4):480-5.
Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects.[Am Rev Respir Dis. 1974]

Tashkin DP, Shapiro BJ, Frank IM

Am Rev Respir Dis. 1974 Apr; 109(4):420-8.
Acute pulmonary physiologic effects of smoked marijuana and oral (Delta)9 -tetrahydrocannabinol in healthy young men.[N Engl J Med. 1973]

Tashkin DP, Shapiro BJ, Frank IM

N Engl J Med. 1973 Aug 16; 289(7):336-41.
Acute and subacute bronchial effects of oral cannabinoids.[Clin Pharmacol Ther. 1984]

Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ

Clin Pharmacol Ther. 1984 Jan; 35(1):26-32.
Bronchodilator effect of delta1-tetrahydrocannabinol.[Br J Clin Pharmacol. 1978]

Hartley JP, Nogrady SG, Seaton A

Br J Clin Pharmacol. 1978 Jun; 5(6):523-5.
Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients.[Thorax. 1976]

Williams SJ, Hartley JP, Graham JD

Thorax. 1976 Dec; 31(6):720-3.

Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms.[Clin Pharmacol Ther. 1979]

Benowitz NL, Rosenberg J, Rogers W, Bachman J, Jones RT

Clin Pharmacol Ther. 1979 Apr; 25(4):440-6.
The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade.[Circulation. 1976]

Kanakis C Jr, Pouget JM, Rosen KM

Circulation. 1976 Apr; 53(4):703-7.
Short-term effects of smoked marihuana on left ventricular function in man.[Chest. 1977]

Tashkin DP, Levisman JA, Abbasi AS, Shapiro BJ, Ellis NM

Chest. 1977 Jul; 72(1):20-6.
Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion.[Clin Pharmacol Ther. 1975]

Benowitz NL, Jones RT

Clin Pharmacol Ther. 1975 Sep; 18(3):287-97.
Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man.[J Clin Pharmacol. 1981]

Benowitz NL, Jones RT

J Clin Pharmacol. 1981 Aug-Sep; 21(S1):214S-223S.
The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.[Am Heart J. 2006]

Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Huestis MA

Am Heart J. 2006 Mar; 151(3):754.e1-754.e5.

Cannabinoids in glaucoma: a primary screening procedure.[J Clin Pharmacol. 1981]

Elsohly MA, Harland E, Murphy JC, Wirth P, Waller CW

J Clin Pharmacol. 1981 Aug-Sep; 21(S1):472S-478S.
Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit.[Curr Eye Res. 1984]

ElSohly MA, Harland EC, Benigni DA, Waller CW

Curr Eye Res. 1984 Jun; 3(6):841-50.
Soft cannabinoid analogues as potential anti-glaucoma agents.[Pharmazie. 2002]

Buchwald A, Derendorf H, Ji F, Nagaraja NY, Wu WM, Bodor N

Pharmazie. 2002 Feb; 57(2):108-14.
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.[Invest Ophthalmol Vis Sci. 2002]

Laine K, Järvinen K, Mechoulam R, Breuer A, Järvinen T

Invest Ophthalmol Vis Sci. 2002 Oct; 43(10):3216-22.
Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides.[Invest Ophthalmol Vis Sci. 2002]

Laine K, Järvinen K, Pate DW, Urtti A, Järvinen T

Invest Ophthalmol Vis Sci. 2002 Feb; 43(2):393-7.
Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits.[Curr Eye Res. 1995]

Pate DW, Järvinen K, Urtti A, Jarho P, Järvinen T

Curr Eye Res. 1995 Sep; 14(9):791-7.
Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana.[Brain Res Mol Brain Res. 1998]

Porcella A, Casellas P, Gessa GL, Pani L

Brain Res Mol Brain Res. 1998 Jul 15; 58(1-2):240-5.
Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol.[Gen Pharmacol. 1984]

Colasanti BK, Brown RE, Craig CR

Gen Pharmacol. 1984; 15(6):479-84.
Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene.[Exp Eye Res. 1984]

Colasanti BK, Powell SR, Craig CR

Exp Eye Res. 1984 Jan; 38(1):63-71.
Marihuana smoking and intraocular pressure.[JAMA. 1971]

Hepler RS, Frank IR

JAMA. 1971 Sep 6; 217(10):1392.
Effect of marihuana on intraocular and blood pressure in glaucoma.[Ophthalmology. 1980]

Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS

Ophthalmology. 1980 Mar; 87(3):222-8.
Delta(9)-tetrahydrocannabinol,, euphoria and intraocular pressure in man.[Ann Ophthalmol. 1975]

Purnell WD, Gregg JM

Ann Ophthalmol. 1975 Jul; 7(7):921-3.
Effects of tetrahydrocannabinol on arterial and intraocular hypertension.[Int J Clin Pharmacol Biopharm. 1979]

Crawford WJ, Merritt JC

Int J Clin Pharmacol Biopharm. 1979 May; 17(5):191-6.
Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.[J Glaucoma. 2006]

Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ

J Glaucoma. 2006 Oct; 15(5):349-53.

Review Cannabinoids and cancer: causation, remediation, and palliation.[Lancet Oncol. 2005]

Hall W, Christie M, Currow D

Lancet Oncol. 2005 Jan; 6(1):35-42.
Review Cannabinoids and cancer.[Mini Rev Med Chem. 2005]

Kogan NM

Mini Rev Med Chem. 2005 Oct; 5(10):941-52.
Review Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review).[Oncol Rep. 2007]

Bifulco M, Laezza C, Gazzerro P, Pentimalli F

Oncol Rep. 2007 Apr; 17(4):813-6.
Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.[J Biol Chem. 2007]

Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R, Alvarez L, Guzmán M, Galve-Roperh I

J Biol Chem. 2007 Mar 2; 282(9):6854-62.
The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells.[Cell Mol Life Sci. 2006]

Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D

Cell Mol Life Sci. 2006 Sep; 63(17):2057-66.
Cannabinoid receptors as novel targets for the treatment of melanoma.[FASEB J. 2006]

Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G, Malumbres M, Guzmán M

FASEB J. 2006 Dec; 20(14):2633-5.
Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.[Cancer Res. 2006]

Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C

Cancer Res. 2006 Jul 1; 66(13):6615-21.
Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.[Cancer Res. 2006]

Carracedo A, Gironella M, Lorente M, Garcia S, Guzmán M, Velasco G, Iovanna JL

Cancer Res. 2006 Jul 1; 66(13):6748-55.
Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria.[Mol Cancer Res. 2006]

Jia W, Hegde VL, Singh NP, Sisco D, Grant S, Nagarkatti M, Nagarkatti PS

Mol Cancer Res. 2006 Aug; 4(8):549-62.
Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression.[Mol Pharmacol. 2006]

McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M

Mol Pharmacol. 2006 Sep; 70(3):897-908.
Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest.[J Biol Chem. 2006]

Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H

J Biol Chem. 2006 Dec 22; 281(51):39480-91.
The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.[Mol Pharmacol. 2006]

Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C, Bifulco M

Mol Pharmacol. 2006 Oct; 70(4):1298-306.
A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.[Br J Cancer. 2006]

Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L

Br J Cancer. 2006 Jul 17; 95(2):197-203.

Review The molecular mechanisms of morphine addiction.[Rev Neurosci. 2006]

McClung CA

Rev Neurosci. 2006; 17(4):393-402.
Review Cocaine: what role does it have in current ENT practice? A review of the current literature.[J Laryngol Otol. 2006]

Harper SJ, Jones NS

J Laryngol Otol. 2006 Oct; 120(10):808-11.
Review Benzodiazepine use, abuse, and dependence.[J Clin Psychiatry. 2005]

O'brien CP

J Clin Psychiatry. 2005; 66 Suppl 2():28-33.
Review Anxiolytic drugs: dependence, addiction and abuse.[Eur Neuropsychopharmacol. 1994]

Lader M

Eur Neuropsychopharmacol. 1994 Jun; 4(2):85-91.
Clinical manifestations of transdermal scopolamine addiction.[Ear Nose Throat J. 1996]

Luetje CM, Wooten J

Ear Nose Throat J. 1996 Apr; 75(4):210-4.
Review A review of the nonmedical use of ketamine: use, users and consequences.[J Psychoactive Drugs. 2000]

Jansen KL

J Psychoactive Drugs. 2000 Oct-Dec; 32(4):419-33.
Review The nonmedical use of ketamine, part two: A review of problem use and dependence.[J Psychoactive Drugs. 2001]

Jansen KL, Darracot-Cankovic R

J Psychoactive Drugs. 2001 Apr-Jun; 33(2):151-8.
Review [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].[Neurologia. 2004]

Linazaroso G, van Blercom N, Lasa A

Neurologia. 2004 Apr; 19(3):117-27.
Review The science of stimulant abuse.[Pediatr Ann. 2006]

Greenhill LL

Pediatr Ann. 2006 Aug; 35(8):552-6.
Cannabinoid receptor type 2 gene is associated with human osteoporosis.[Hum Mol Genet. 2005]

Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, Essig J, Erxlebe E, Bab I, Kubisch C, de Vernejoul MC, Zimmer A

Hum Mol Genet. 2005 Nov 15; 14(22):3389-96.
Peripheral cannabinoid receptor, CB2, regulates bone mass.[Proc Natl Acad Sci U S A. 2006]

Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I

Proc Natl Acad Sci U S A. 2006 Jan 17; 103(3):696-701.
Review Evidence for novel cannabinoid receptors.[Pharmacol Ther. 2005]

Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G

Pharmacol Ther. 2005 May; 106(2):133-45.
In silico patent searching reveals a new cannabinoid receptor.[Trends Pharmacol Sci. 2006]

Baker D, Pryce G, Davies WL, Hiley CR

Trends Pharmacol Sci. 2006 Jan; 27(1):1-4.

Save items

Similar articles in PubMed

Cited by other articles in PMC

Links

Recent Activity